Philadelphia, 5 March 2009 – Elsevier is honored to announce today that Lajos P. Balogh, PhD, has been named the new Editor-in-Chief of 
Nanomedicine: Nanotechnology, Biology and Medicine, an online journal published by Elsevier.
Dr. Balogh has been involved in nanotechnology research since 1996 and is presently active in various interdisciplinary directions. His major research interest is the construction of well-defined organic/inorganic hybrid medical nanodevices for targeted detection, imaging, and biophysical therapy of cancer based on dendrimers, smart contrast agents, and radioactive nanocomposites. He has published over 180 scientific papers and has been awarded 12 patents on dendrimers, nanocomposites, cancer imaging and treatment, analytical chemistry, separation science, technology, polymer synthesis and characterization.
Dr. Balogh is currently a Professor of Biomedical Nanotechnology and Director of Nanotechnology Research in the Department of Radiation Medicine at the Roswell Park Cancer Institute, Buffalo, NY. He is also the Co-Director of the NanoBiotechnology Center at Roswell and Professor of Oncology at the University at Buffalo, SUNY.
Kate Williamson, Elsevier Associate Publisher for Nanomedicine: Nanotechnology, Biology and Medicine, commented: “We are so pleased to welcome Dr. Balogh as Editor-in-Chief of Nanomedicine: NBM. Dr. Balogh's expertise in the field will be a tremendous asset to the journal. We look forward to working with Dr. Balogh and the editorial team to carry out his vision for the journal.”
# # #
About Nanomedicine: Nanotechnology, Biology and Medicine
Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM) is an international, peer-reviewed journal. Each quarterly issue of Nanomedicine: NBM presents basic, clinical, and engineering research in the field of nanomedicine. Article categories include basic, diagnostic, experimental, clinical, engineering, pharmacologic, and toxicologic nanomedicine. The Journal is indexed in MEDLINE from Volume 1, issue 1 and is available online at
www.nanomedjournal.com.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as
ScienceDirect,
MD Consult,
Scopus, bibliographic databases, and online reference works.
Elsevier is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of
Reed Elsevier Group plc, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media Contact:
Caroline Foote
Elsevier
+1 215 239 3652
c.foote@elsevier.com
